If the page does not redirect, click here
Combination breast cancer therapy targets tumor cells and the blood vessels that feed them
Each day, normal human cell tissues express a protein known as p53 that wages war against potential malignancies. However, between 30 and 40 percent of human breast cancers express a defective (mutant) form of p53 that helps cancer cells proliferate and grow. Now, researchers at the University of Missouri have found that combining a cancer therapy, which activates mutant p53 and is currently under a clinical trial, with a second drug therapy that helps suppress tumor blood vessels found in cancer cells, can help significantly reduce the spread of breast cancer tumors while also causing cancer cell death.